Moreover, PARPi administration to breast cancer cell lines further enhance PD-L1 by inactivating GSK3β (48), thus explaining the benefit obtained by the combination of PARPi and anti-PD-L1 therapy (11). Here, CD274 is linked to breast carcinoma.